sorry, we can't preview this file

...but you can still download Supplementary Material.docx
Supplementary Material.docx (979.73 kB)

FMB-2021-0215 Supplementary Material

Download (979.73 kB)
figure
posted on 23.03.2022, 09:00 by Camila Maríngolo Ribeiro, Júlia A. Grecco, Débora L. Bellato, Aryadne Larissa de Almeida, Vanessa Pietrowski Baldin, Katiany Rizzieri Caleffi-Ferracioli, Fernando Rogério Pavan
Supplementary figure 1. Relative fluorescence due to the accumulation of ethidium bromide in the clinical isolate of Mycobacterium tuberculosis CF 110 after different pretreatments and in the presence of efflux pump inhibitors.

CCCP = m-chlorophenyl hydrazine; VP = verapamil; RES = reserpine; OFL = ofloxacin. The results are the mean of two independent assays.


Supplementary figure 2. Relative fluorescence due to the accumulation of ethidium bromide in the clinical isolate of Mycobacterium tuberculosis CF 169 after different pretreatments and in the presence of efflux pump inhibitors.

CCCP = m-chlorophenyl hydrazine; VP = verapamil; RES = reserpine; OFL = ofloxacin;
STP = streptomycin. The results are the mean of two independent assays.


Supplementary figure 3. Relative fluorescence due to the accumulation of ethidium bromide in the laboratorial strains of Mycobacterium tuberculosis H37Rv after different pretreatments and in the presence of efflux pump inhibitors.

CCCP = m-chlorophenyl hydrazine; VP = verapamil; RES = reserpine; OFL = ofloxacin;
STP = streptomycin. The results are the mean of two independent assays.

Funding

This study was financed by São Paulo Research Foundation (FAPESP 2018/02344-2, 2018/12135-1), São Paulo State University and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001.

History